These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 10415906)

  • 1. Inhibition of central monoamine oxidase by imidazoline2 site-selective ligands.
    Lalies MD; Hibell A; Hudson AL; Nutt DJ
    Ann N Y Acad Sci; 1999 Jun; 881():114-7. PubMed ID: 10415906
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between imidazoline(2) sites and monoamine oxidase.
    Paterson LM; Tyacke RJ; Nutt DJ; Hudson AL
    Ann N Y Acad Sci; 2003 Dec; 1009():353-6. PubMed ID: 15028610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
    Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K
    J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenylethanolamine is a specific substrate for type B monoamine oxidase.
    Edwards DJ
    Life Sci; 1978 Sep; 23(11):1201-7. PubMed ID: 713694
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.
    Alemany R; Olmos G; García-Sevilla JA
    Br J Pharmacol; 1995 Feb; 114(4):837-45. PubMed ID: 7773544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
    Gerardy J
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain.
    Garrick NA; Murphy DL
    Psychopharmacology (Berl); 1980; 72(1):27-33. PubMed ID: 6781004
    [No Abstract]   [Full Text] [Related]  

  • 8. Substrate specificity of the different forms of monoamine oxidase in rat liver mitochondria.
    Ekstedt B
    Biochem Pharmacol; 1976 May; 25(10):1133-8. PubMed ID: 938537
    [No Abstract]   [Full Text] [Related]  

  • 9. Substrate selectivity of type A and type B monoamine oxidase in rat brain.
    Kinemuchi H; Wakui Y; Kamijo K
    J Neurochem; 1980 Jul; 35(1):109-15. PubMed ID: 6778959
    [No Abstract]   [Full Text] [Related]  

  • 10. The effects of chronic administration of inhibitors of flavin and quinone amine oxidases on imidazoline I(1) receptor density in rat whole brain.
    Holt A; Todd KG; Baker GB
    Ann N Y Acad Sci; 2003 Dec; 1009():309-22. PubMed ID: 15028605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidation of phenylethanolamine and octopamine by type A and type B monoamine oxidase. Effect of substrate concentration.
    Suzuki O; Katsumata Y; Oya M; Matsumoto T
    Biochem Pharmacol; 1979 Aug; 28(15):2327-32. PubMed ID: 387041
    [No Abstract]   [Full Text] [Related]  

  • 12. The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications.
    Fowler CJ; Oreland L; Callingham BA
    J Pharm Pharmacol; 1981 Jun; 33(6):341-7. PubMed ID: 6115003
    [No Abstract]   [Full Text] [Related]  

  • 13. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
    Kumagae Y; Matsui Y; Iwata N
    Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro].
    Gol'dina OA; Zagorevskiĭ VA; Lopatina KI; Sokolova TV; Gankina EM
    Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of monoamine oxidase by clorgyline and deprenyl in circumventricular structures of rat brain.
    Kinemuchi H; Wakui Y; Arai Y; Kamijo K
    Biochem Pharmacol; 1980 Oct; 29(20):2871-4. PubMed ID: 6776962
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues.
    Celada P; Artigas F
    J Neurochem; 1993 Dec; 61(6):2191-8. PubMed ID: 7504085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution and inhibition characteristics of human brain monoamine oxidase.
    Owen F; Cross AJ; Lofthouse R; Glover V
    Biochem Pharmacol; 1979 Apr; 28(7):1077-80. PubMed ID: 444264
    [No Abstract]   [Full Text] [Related]  

  • 18. Phenylethylamine--deamination by multiple types of monoamine oxidase.
    Dial EJ; Clarke DE
    Biochem Pharmacol; 1978; 27(19):2374-5. PubMed ID: 728190
    [No Abstract]   [Full Text] [Related]  

  • 19. Modulation of MAO activity by imidazoline and guanidine derivatives.
    Raasch W; Muhle H; Dominiak P
    Ann N Y Acad Sci; 1999 Jun; 881():313-31. PubMed ID: 10415932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of rat brain cytosolic monoamine oxidase activity by clorgyline. Comparison with (-)-deprenyl and MDL 72145.
    Azam M; Jain S; Baquer NZ
    Biochem Pharmacol; 1990 Nov; 40(10):2215-8. PubMed ID: 2123104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.